Serge Belanger's Stock Ratings

Needham Analyst

Serge Belanger is an analyst at Needham. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 02/22/2025

Overall Average Return

12.0%

Smart Score

Overall Average Return Percentile

62nd

Number of Ratings

358

Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

Breaking Down Evolus: 4 Analysts Share Their Views

4 Analysts Have This To Say About Arcutis Biotherapeutics

What 8 Analyst Ratings Have To Say About Pacira BioSciences

Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings)

4 Analysts Have This To Say About Evolus

6 Analysts Assess Pacira BioSciences: What You Need To Know

Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews

Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham

Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, and undervaluation.

Breaking Down Liquidia: 4 Analysts Share Their Views

Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook